updat spinraza data pre-symptomat sma patient suggest
earlier morn releas updat result
on-going nurtur studi spinraza pre-symptomat infant
like develop type sma receiv first dose spinraza six
week age data march median follow-up approxim
three year use age proxi follow-up aliv without need
perman ventil sit independ walk
independ mani within normal time-frame toddler
note walk independ numer increas
last interim analysi data may chop intend ceil mean score
patient smn copi respect repres
margin increas previou interim look respect
gener difficult compar zolgensma sustain need perman
ventil seem hard beat make decis forgo spinraza favor
gene therapi difficult one believ worth note result clearli
perfect albeit miracul support belief longer term mani
patient receiv multipl type treatment maxim function abil
strong spinraza rais stake like whole aso platform
believ use around incomplet gene therapi correct mani complex
diseas said recent launch like continu
weigh increasingli stock convers payor suggest
dont expect pay gene therapi lifetim spinraza without data
support combin current spinraza nurtur data better
anyth seen superior princip reflect
earli dose nurtur week vs month overal tens
situat play time unclear continu
model rel flat spinraza revenu next year top expect
modest competit threat build slowli
rate tg provid price target neutral rate stock
idc btig estim compani document
million except per share amount
downgrad buy neutral null aducanumab readout march make appropri
updat model recogn lead compani neurolog space seem
significantli behind develop gene therapi like novarti nv rate voyag buy
pt therapeut get mab protein across blood brain barrier like denali approach
tecfidera front buy analyst timothi chiang pt ipr cover patent like
continu weigh next month
vs tecfidera ms data
psp data
cle/sl data
natalizumab epilepsi data
opicinumab ms data
parkinson diseas data
manag guidanc flat sale two year follow increas
base princip launch vumer
po adopt price point
spinraza conserv model attrit sale growth follow market
entri zolgensma risdiplam
zolgensma risdiplam significantli erod spinraza sale
neg ipr decis overturn tecfidera patent
potenti zolgensma risdiplam launch significantli erod spinraza sale
global
biopharmaceut compani
discov develop
commerci therapi
tecfidera tysabri avonex
plegridi headquart
cambridg found
thoma shrader harrison incom total research sell gener loss asset liabil held sale- amort acq intang fair valu adj contig collabor profit acquir in-process research restructur total oper interest incom expens incom incom tax equiti loss investe net tax- net incom non-controlling net incom total non- non- net incom ep non- ep weight averag share outstand
btig cover compani mention report
appendix analyst certif import disclosur
